EU Allocates €6.5M To Study Psychedelics For Pulmonary Disorder, Multiple Sclerosis, ALS, Parkinson's

This article was originally published on The Dales Report and appears here with permission.

The European Union has allocated €6.5 million from its Horizon Europe program to finance PsyPal, a multisite clinical study focusing on the use of psychedelic-assisted therapy. This initiative, led by the University Medical Centre Groningen (UMCG) in the Netherlands and in collaboration with HumanKindLabs, represents the EU’s first investment in this area of research. The study aims to evaluate the effectiveness of psilocybin therapy in reducing psychological and existential distress in patients with progressive, incurable diseases needing palliative care, specifically targeting conditions like chronic obstructive pulmonary disorder (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and atypical Parkinson’s disease (APD).

The trial, set to include over one hundred patients across four European clinical sites, will administer two therapy sessions where participants will receive either psilocybin or a placebo. This study is pivotal as it delves into the safety and impact of psilocybin on palliatively treated patients outside of oncology, aiming to ease patient suffering and assess long-term effects on both patients and their families.

Funded by Horizon Europe, the EU’s primary program for research and innovation, the trial benefits from an environment that promotes collaborative research aimed at addressing significant challenges. This funding for the EU psychedelic trial highlights the growing acknowledgment of the potential benefits of psychedelic treatments, particularly for patients unresponsive to conventional treatments, and seeks to fortify international and interdisciplinary research collaboration.

The conditions addressed in the PsyPal EU psychedelic trial significantly affect patients’ autonomy and psychological well-being, with a notable prevalence of depression and anxiety symptoms. This reality underscores the necessity for innovative treatment methods, as traditional approaches often fail to meet the complex needs of palliative care patients. Psychedelic-assisted psychotherapy, especially with psilocybin, shows promise in not only managing symptoms of depression and anxiety but also in enhancing spiritual well-being and overall life quality.

The PsyPal EU psychedelic trial extends beyond clinical investigation; it is a collective endeavor involving a consortium of 19 European organizations from 9 countries. This consortium unites a diverse group of professionals, indicating a commitment to a comprehensive approach that combines psychotherapy and pharmacotherapy. The project’s goal is to achieve lasting well-being for patients and their families, integrating peer support and digital resources to support patients nearing life’s end.

This consortium is not merely focused on the clinical aspect but is also dedicated to maintaining the highest ethical standards in clinical and research practices, adhering to regulations and recommendations from ethics committees and regulatory authorities. The varied nature of the organizations involved in the consortium reflects the multifaceted approach of the PsyPal trial, aiming for a holistic impact on the lives of patients undergoing palliative care.

This article is from an external unpaid contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Image generated by AI